Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Orchestra Biomed Holdings Inc maintains a gross margin of 99.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 21.85%, while the net margin is 20.20%. These profitability ratios, combined with a Return on Equity (ROE) of -122.40%, provide a clear picture of how effectively OBIO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, OBIO competes directly with industry leaders such as TLSI and CVRX. With a market capitalization of $238.18M, it holds a leading position in the sector. When comparing efficiency, OBIO's gross margin of 99.84% stands against TLSI's 86.66% and CVRX's 86.28%. Such benchmarking helps identify whether Orchestra Biomed Holdings Inc is trading at a premium or discount relative to its financial performance.
